How would you approach systemic therapy for a pre-menopausal woman with ER+/PR+/HER2 positive breast cancer who had a local recurrence 6 months after completing adjuvant TCH and a year of trastuzumab + tamoxifen?  

Would you consider neoadjuvant or adjuvant treatment and if so, which therapies? Patient initially had pT2N0 disease and recurrent disease is also ER+/PR+/HER2 positive.

Answer from: Medical Oncologist at Academic Institution
Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
In a situation like this where there is a local re...
Medical Oncologist at Northwestern Medicine Cancer Center at KishHealth
Stop after a year. 
Medical Oncologist at NYU Winthrop Hospital
I will use Trastuzumab DXd based on DESTINY-Breast...
Sign in or Register to read more